Pluripotent Stem Cells

Volume 997 of the series Methods in Molecular Biology pp 149-161


Highly Efficient Directed Differentiation of Human Induced Pluripotent Stem Cells into Cardiomyocytes

  • Paul W. BurridgeAffiliated withInstitute for Cell Engineering, Johns Hopkins University School of Medicine
  • , Elias T. ZambidisAffiliated withDivision of Pediatric Oncology, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

* Final gross prices may vary according to local VAT.

Get Access


Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes are a novel source of cells for patient-specific cardiotoxicity drug testing, drug discovery, disease modeling, and regenerative medicine. We describe a versatile and cost-effective protocol for in vitro cardiac differentiation that is effective for a wide variety of hiPSC and human embryonic stem cell (hESC) lines. This highly optimized protocol produces contracting human embryoid bodies (hEB) with a near total efficiency of 94.7  ±  2.4% in less than 9 days, and minimizes the variability in cardiac differentiation commonly observed between various hiPSC and hESC lines. The contracting hEB derived using these methods contain high percentages of pure functional cardiomyocytes, highly reproducible electrophysiological profiles, and pharmacologic responsiveness to known cardioactive drugs.

Key words

Human embryonic stem cell Induced pluripotent stem cell Heart Cardiac Cardiomyocyte Differentiation Forced aggregation